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Background: Diagnosis of chronic pulmonary aspergillosis (CPA) is challenging.
Symptoms are unspecific or missing, radiological findings are variable and proof of
mycological evidence is limited by the accuracy of diagnostic tests. The goal of this
study was to investigate diagnostic performance of galactomannan (GM), the newly
formatted Aspergillus-specific lateral-flow-device test (LFD), and a number of cytokines
in bronchoalveolar lavage fluid (BALF) samples obtained from patients with CPA, patients
with respiratory disorders without CPA and healthy individuals.
Methods: Patients with CPA (n = 27) and controls (n = 27 with underlying respiratory
diseases but without CPA, and n = 27 healthy volunteers) were recruited at the Medical
University of Graz, Austria and the Research Center Borstel, Germany between 2010
and 2018. GM, LFD and cytokine testing was performed retrospectively at the Research
Center Borstel.
Results: Sensitivity and specificity of GM testing from BALF with a cut off level of ≥0.5
optical density index (ODI) was 41 and 100% and 30 and 100% with a cut off level of
≥1.0 ODI. ROC curve analysis showed an AUC 0.718 (95% CI 0.581–0.855) for GM for
differentiating CPA patients to patients with other respiratory diseases without CPA. The
LFD resulted positive in only three patients with CPA (7%) and was highly specific. CPA
patients did not differ significantly in the BALF cytokine profile compared to patients with
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respiratory disorders without CPA, but showed significant higher values for IFN-γ, IL-1b,
IL-6, IL-8, and TNF-α compared to healthy individuals.
Conclusion: Both GM and LFD showed insufficient performance for diagnosing CPA,
with sensitivities of BALF GM below 50%, and sensitivity of the LFD below 10%. The
high specificities may, however, result in a high positive predictive value and thereby help
to identify semi-invasive or invasive disease.
Keywords: chronic pulmonary aspergillosis, bronchoalveolar lavage, galactomannan, lateral-flow device,
cytokines
INTRODUCTION
Diagnosis of chronic pulmonary aspergillosis (CPA) is
challenging. Symptoms are unspecific, radiological findings
are variable and proof of mycological evidence is limited by
the paucity of diagnostic tests. Current guidelines recommend
establishing diagnosis based on several characteristics including
a radiological pattern consistent with CPA, proof of mycological
evidence and exclusion of alternative diagnosis (Denning
et al., 2016; Patterson et al., 2016). Consequently, patients
usually undergo bronchoscopy to achieve both exclusion
of alternative diagnosis (e.g., lung cancer or mycobacterial
infection) and to obtain bronchoalveolar lavage fluid (BALF)
at the primary site of infection to obtain mycological
evidence.
Galactomannan (GM) testing from BALF is well established in
the diagnosis of pulmonary invasive aspergillosis (IPA) (Ullmann
et al., 2018), but evidence about the performance in CPA patients
is limited. Only four studies have reported GM test results from
BALF in CPA patients so far. Sensitivity and specificity were
between 78 and 92 and 76 and 90% with an optical density index
(ODI) ≥0.5, respectively (Park et al., 2011; Kono et al., 2013;
Urabe et al., 2017) and 77–77% with an ODI ≥0.4 (Izumikawa
et al., 2012).
The Aspergillus-specific lateral-flow device (LFD) is an
immuno-chromatographic assay that detects extracellular
glycoprotein antigen circulating in BALF secreted during
active growth of the fungus (Thornton, 2008). A first
clinical evaluation of the newly formatted and CE marked
point-of-care LFD in BALF showed a sensitivity of
71% and a specificity of 100% for patients at risk for
IPA (Hoenigl et al., 2018). Data about the performance
of the LFD in BALF from patients with CPA are
lacking.
Genetic association studies of genes involved in the immune
response to Aspergillus fumigatus indicated that patients with
CPA might differ from other patients in the cytokine profile,
however, studies comprehensively investigating cytokines in
BALF from CPA patients vs. controls are missing (Sambatakou
et al., 2006; Smith et al., 2014).
We aimed to investigate diagnostic performance of
GM and LFD testing, as well as various cytokine levels
in BALF samples obtained from patients with CPA
according to ESCMID/ERS/ECMM definition, patients
with respiratory disorders without CPA and healthy
individuals.
MATERIALS AND METHODS
Study Population
Patients with CPA were recruited at the Medical University of
Graz, Austria (n = 4) and the Research Center Borstel, Germany
(n = 23). Healthy volunteers (n = 27) were recruited at the
Research Center Borstel, Germany and were asked to undergo
bronchoscopy for study purposes, which served as control
group (Approval number: AZ 15–194). Patients with respiratory
disorders without CPA infection who received bronchoscopy and
BALF as part of routine clinical and subsequent microbiologic
work-up due to suspicion of pulmonary infection were recruited
at the Medical University of Graz, Austria (n = 27). Inclusion
of residual BALF samples of patients was approved by the
local ethics committee at the University of Lübeck, Germany
(Approval numbers: AZ 12–220, AZ 14–225, and AZ 18–105)
and the Medical University of Graz, Austria (Approval number:
25–221 ex 12/13).
Case Definition
Criteria for CPA were based on the diagnostic criteria expressed
by the ESCMID/ERS/ECMM guideline including a) one or more
cavities with or without a fungal ball present or nodules on
computed tomography scan, b) direct evidence of Aspergillus
infection or an immunological response to Aspergillus spp. (e.g.,
Aspergillus-specific IgG antibody), and exclusion of alternative
diagnosis, all present for at least 3 month or 1–3 month in case
of subacute invasive aspergillosis (SAIA), respectively (Denning
et al., 2016; Salzer et al., 2017).
Clinical Samples
Bronchoscopies with BALF according to professional
recommendations were performed in all patients at the
Medical Clinic of the Research Center Borstel, Germany and the
Medical University of Graz, Austria (Haussinger et al., 2004).
All BALF samples were stored at −70◦C and samples from the
Medical University of Graz, Austria shipped on dry ice to the
Medical Clinic of the Research Center Borstel, Germany, where
GM, LFD and cytokine testing was performed in June 2018.
BALF samples from the Medical University of Graz were, in part,
published before (Prattes et al., 2014).
Aspergillus Galactomannan Antigen
Assay
BALF Aspergillus GM was determined by the Platelia EIA (Bio-
Rad Laboratories, Munich, Germany) in clinical routine at
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the Medical Clinic of the Research Center Borstel, Germany
according to the manufacturer’s instructions. BALF samples were
processed in accordance to the manufactures protocol. While our
analysis primarily focused on the recommended 1.0 ODI cut-
off for BALF, we also evaluated a 0.5 GM ODI cut-off, following
previous evidence that the 0.5 ODI cut off is preferable in patients
on mold-active antifungals (Eigl et al., 2015, 2017).
Newly Formatted Lateral-Flow Device
The newly formatted CE marked Aspergillus LFD (OLM
Diagnostics, Newcastle upon Tyne, United Kingdom) was
performed in accordance to the manufactures protocol (Hoenigl
et al., 2018). Stored BALF samples were thawed, vortexed, and
centrifuged for 1 min at 14,000 × g. Seventy microliter of
untreated BALF sample were applied to the port of the cassette,
with results read 15 min later. Two interpreters read LFD test
results independently without knowing the CPA status, ensuring
an unbiased interpretation of the test results. Appearance of the
test and the control line were considered as positive test result.
Quantification of Cytokines
Levels of IL-1β, IL-6, IL-8, IL-10, IL-15, interferon (IFN)-γ,
and tumor necrosis factor (TNF)-α were analyzed by using the
Meso Scale Discovery (MSD) U-Plex Platform (MSD, Rockville,
MD, Unites States). The panel was selected based on previous
findings of BALF cytokines in CPA and invasive aspergillosis
(Sambatakou et al., 2006; Smith et al., 2014; Heldt et al., 2017;
Heldt et al., 2018). According to the manufacturer’s instructions1
the U-Plex linker (= binding to the U-Plex plate) was coupled
to the specific biotinylated capture antibodies (= conjugated with
electrochemiluminescent label), followed by the preparation of
the multiplex coating solution. Fifty microliter of the multiplex
coating solution were added to each 96-well U-Plex plate for a
1 h incubation. Twenty-five microliter BALF and 25 µL standard
were incubated in the 96-well plate. Fifty microliter detection
antibody was added for 1 h incubation to complete the sandwich
immunoassay followed by adding 150 µL of 2× Reading Buffer.
Each incubation was performed for 1 h on a shaker at room
temperature, afterward the solutions was washed off. Analyses
were performed on the MSD instrument by measuring the
intensity of emitted light providing a quantitative measure.
Statistical Analyses
Statistical analysis was performed with R Version 3.5.0. Kruskal–
Wallis rank sum and pairwise Wilcoxon rank sum test were
used to compare the patient characteristics and biomarker
values in the three groups (patients with CPA, patients with
respiratory disorders without CPA and healthy individuals). The
Tukey Test was used to display the mean value differences.
In this context, a power analysis was also conducted. Receiver
operating characteristic (ROC) curve analyses were performed
and Areas under the Curve (AUC) including 95% confidence
interval were displayed to assess the diagnostic discriminatory
ability of biomarkers to distinguish between CPA patients and
healthy individuals and between CPA patients and patients with
respiratory disorders without CPA.
1https://www.mesoscale.com
RESULTS
A total of 81 patients were included in this analysis. Twenty-
seven patients were classified as CPA and were compared to
two control groups consisting of 27 patients with respiratory
disorders without evidence of CPA and 27 healthy individuals.
CPA patients were classified as chronic cavitary pulmonary
aspergillosis (CCPA) (n = 12), single/simple aspergilloma (n = 6),
Aspergillus nodules (n = 4), and subacute invasive aspergillosis
[SAIA (n = 5)]. In more than one third of CPA patients (37%;
10/27) the diagnosis was histologically proven with exclusion of
SAIA or IPA.
For all patients enough BALF sample volume was available
for measurements of GM, LFD and cytokines. Patients’
characteristics and mean values for GM and cytokines as well as
positive test results for the LFD are displayed in Table 1.
Aspergillus Galactomannan Antigen
Assay
Depending on the cut-off used, GM antigen assay from BALF
was positive in 8/27 CPA patients (30%; cut off 1.0 ODI) and in
11/27 CPA patients (41%; cut off 0.5 ODI), respectively. Neither
patients with respiratory disorders without CPA nor healthy
individuals had a positive GM test result from BALF with an
ODI ≥ 1.0 (specificities 100% for both control groups). Two
patients with respiratory disorders without CPA had a positive
GM test result from BALF with an ODI ≥ 0.5, but none from
the healthy individuals (specificity 93 and 100%, respectively)
(Table 2). Among 10 patients with histologically proven diagnosis
of CPA, eight had a GM test result <0.5 ODI and one patient
had a GM test result of 0.7 ODI, while only 1 had a GM result
> 1.0 ODI.
The diagnostic performance of the GM test tended to be
higher when COPD was present in CPA patients (sensitivity 46%
vs. 38%; cut off 0.5 ODI and 46% vs. 19%; cut off 1.0 ODI
respectively) (Table 3).
The distribution of GM test results for all three cohorts
is shown in Figure 1. GM values were significantly higher
in CPA samples compared to patients with respiratory
disorders without CPA (p = 0.013) and healthy individuals
(p < 0.001). No significant differences in GM values were
found between healthy individuals and patients with other
respiratory diseases without CPA (p = 0.081) (Table 3).
Tukey test showed a significant difference in mean values for
GM test between CPA patients compared to patients with
respiratory disorders without CPA and to healthy individuals
(Figure 2).
ROC curve analysis showed an AUC 0.718 (95% CI 0.581–
0.855) for differentiating CPA patients from patients with other
respiratory diseases without CPA (Figure 3) and an AUC of
0.875 (95% CI 0.782–0.968) for differentiating CPA patients from
healthy individuals (Figure 3).
Newly Formatted Lateral-Flow Device
The Aspergillus LFD showed positive test results in two CPA
patients (sensitivity 7%) and in one patient with respiratory
disorder without CPA, but none in healthy volunteers (specificity
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96 and 100%, respectively). Both CPA patients with a positive
LFD had a high GM test result of 14.0 and 5.4 ODI, respectively,
while the one patient without CPA had a negative GM test result
of 0.38 ODI.
Cytokines
Median and standard deviation of CPA patients vs. controls
including patients with respiratory disorders without CPA and
healthy individuals are depicted Table 1. Box plots for IL-
1β, IL-6, IL-8, IL-10, IL-15, TNF-α, and IFN-γ are depicted
in Figure 4. AUC for BALF cytokines for differentiating
CPA patients vs. controls including patients with respiratory
disorders without CPA and healthy individuals are depicted in
Table 2.
CPA patients did not differ significantly in the BALF cytokine
profile compared to patients with respiratory disorders without
CPA, but showed significant higher values for IFN-γ, IL-
1b, IL-6, IL-8, and TNF-α compared to healthy individuals
(Table 2). Patients with respiratory disorders without CPA had
also significantly higher values for IFN-γ, IL-1b, IL-6, IL-8, and
TNF-α compared to healthy individuals.
Sensitivity of IL-1b, IL-6, and IL-8 tended to be higher in
patients without COPD, but at the expense of specificity. The
sensitivity of TNF-α tended to be higher when COPD was present
in CPA patients (Table 2).
DISCUSSION
We evaluated diagnostic performance of GM and LFD testing,
which are routinely used for the diagnosis of invasive pulmonary
aspergillosis (IPA), in patients with CPA compared to patients
with respiratory disorders without CPA and healthy individuals.
We also explored the diagnostic potential of cytokine levels in
BALF in these patient cohorts.
In the present study the sensitivity of the GM test from BALF
for CPA (according to ESCMID/ERS/ECMM definition) was
TABLE 1 | Demographic data, underlying respiratory disorders and mean values with standard deviations of GM, LFD, and cytokine levels.
All patients CPA Respiratory disorders without CPA Healthy individuals P-value
No. of patients 81 27 27 27
Sex
- Male 48 (60.0%) 17 (63.0%) 15 (57.3%) 16 (59.3%) 0.922
- Female 32(40.0%) 10 (37.0%) 11 (42.7%) 11 (40.7%)
Age (median. range) 59 (20–88) 63 (28–88) 66 (48–86) 29 (20–74) <0.001∗
Underlying Respiratory Disorder
- Asthma 2 (2.5%) 2 0 0 NA
- Bronchiectasis 4 (5%) 3 1 0 NA
- COPD 32 (40%) 12 20 0 0.442
- Lung fibrosis 2(2.5%) 0 2 0 NA
- NTM 2(2.5%) 2 0 0 NA
- Prior pulmonary TB 7 (8.75%) 6 1 0 NA
- Recurrent aspirations 1(1.25%) 1 0 0 NA
- Sarkoidosis 6 (7.5%) 2 4 0 NA
- Lung cancer 6(7.5%) 2 4 0 NA
- Pulmonary embolism 1(1.25%) 1 0 0 NA
- LTOT 1(1.25%) 0 1 0 NA
- OSAS 2(2.5%) 0 2 0 NA
- Pneumonia 2(2.5%) 0 2 0 NA
Tests
GM (ODI mean, range) 0.69 ± 1.98 1.66 ± 3.22 0.24 ± 0.17 0.15 ± 0.05 0.006∗
Positive LFD 3 2 1 0 0.358
Cytokines (pg/ml, mean, range)#
- IFN-γ 102.11 ± 569.34 33.46 ± 75.10 223.77 ± 893.64 1.07 ± 0.88 0.372
- IL-10 2.410 ± 8.65 0.46 ± 0.83 5.43 ± 12.10 0.00 ± 0 0.066
- IL-15 2.29 ± 4.07 2.33 ± 3.37 3.64 ± 5.70 0.92 ± 0.70 0.059
- IL-1b 121.79 ± 507.97 113.74 ± 342.34 255.84 ± 811.74 0.74 ± 0.66 0.189
- IL-6 47.29 ± 102.45 51.38 ± 91.45 92.19 ± 140.45 0.41 ± 0.69 0.004∗
- IL-8 1390.34 ± 2087.14 1643.67 ± 2120.37 2545.85 ± 2369.79 24.29 ± 18.76 <0.001∗
-TNF-α 4.97 ± 19.64 2.00 ± 4.38 10.08 ± 29.61 0.00 ± 0 0.213
COPD, Chronic obstructive pulmonary disease; CPA, Chronic pulmonary aspergillosis; GM, Galactomannan; IFN, Interferon; IL, Interleukins; LFD, Lateral-flow device;
LTOT = Long-term oxygen therapy; NTM, Non-tuberculous mycobacteria; ODI, Optical density index; OSAS, Obstructive sleep apnea syndrome; TB, Tuberculosis; TNF,
Tumor necrosis factor. #For one patient in the group of respiratory disorders without CPA cytokine levels were not determined due to insufficient BALF volume. ∗P-value
<0.05 statistically significant.
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TABLE 3 | P-values of pairwise Wilcoxon rank sum test for GM and cytokines.
CPA vs. respiratory
disorders without
CPA
CPA vs.
healthy
individuals
Respiratory disorders
without CPA vs. healthy
individuals
GM p = 0.013∗ p < 0.001∗ p = 0.081
IFN- γ p = 0.477 p = 0.001∗ p < 0.001∗
IL-10 p = 0.541 p = 0.072 p = 0.057
IL-15 p = 1.00 p = 1.00 p = 0.14
IL-1b p = 0.96 p < 0.001∗ p < 0.001∗
IL-6 p = 0.15 p < 0.001∗ p < 0.001∗
IL-8 p = 0.089 p < 0.001∗ p < 0.001∗
TNF-α p = 0.609 p = 0.008∗ p = 0.003∗
CPA, Chronic pulmonary aspergillosis; GM, Galactomannan; IFN, Interferon; TNF,
Tumor necrosis factor. ∗P-value <0.05 statistically significant.
considerably lower than previously reported with sensitivities of
30% (cut off 1.0 ODI) and 41% (cut off 0.5 ODI), respectively.
Strikingly, 80% of histologically proven cases of CPA had a
negative GM test result when using the 0.5 ODI cut-off (and
90% when using the 1.0 ODI cut off). Previous studies reported
higher sensitivities between 77 and 92% for a cut off ≥0.5 ODI
or ≥0.4 ODI (Park et al., 2011; Izumikawa et al., 2012; Kono
et al., 2013; Urabe et al., 2017). We suggest that one main
reason is that studies demonstrating a higher sensitivity from
BALF in CPA patients may have included a considerably higher
proportion of patients with SAIA (formally chronic necrotizing
or semi-IPA), which is in fact an invasive form of the disease
and very similar to IPA. This has been demonstrated by the
study of Kono et al. (2013) who included a total of 7 patients
with pulmonary aspergillosis in their analysis including five
patients with SAIA (sensitivity 86%; cut-off≥0.5 ODI). The most
recent study by Urabe et al. (2017) who reported a sensitivity of
78% for BALF GM testing (cut-off ≥0.5 ODI) among 27 CPA
FIGURE 2 | Shows differences in mean of GM antigen levels with 95%
confidence interval for patients with CPA and for controls including patients
with respiratory disorders without CPA and healthy individuals.
patients did not provide information on the SAIA proportion
nor on exact GM values hampering the interpretation of the
data.
FIGURE 1 | Box plot showing the distribution of GM antigen levels for patients with CPA and controls including patients with respiratory disorders without CPA and
healthy individuals.
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FIGURE 3 | Receiver operating characteristics (ROC) curve analysis of galactomannan test results in bronchoalveolar lavage fluid (BALF) for patients with chronic
pulmonary aspergillosis (CPA) and patients with respiratory disorders without CPA (A) as well as for patients with CPA and healthy individuals (B).
Another study by Izumikawa et al. (2012) reported a sensitivity
of 77% (cut off 0.4 ODI) for the GM test from BALF and
included 18 CPA patients. Although they did not classify CPA
subtypes, inclusion criteria considered SAIA and we suggest that
a considerably proportion might have had SAIA because very
high GM test results between 7.3 and 14.1 ODI were observed in
7/18 patients. In contrast, in our study only 3/27 CPA patients had
a GM test result >5.0 ODI. We suggest that these three patients
might have in fact had SAIA supported by the fact that the two
positive LFD test results from BALF in our study were seen in
those patients with the highest GM test results.
The highest sensitivity of 92% for GM from BALF (cut off
≥0.5 ODI) was reported in patients with single aspergilloma
(Park et al., 2011). Interestingly, 75% of all patients included in
that study (n = 48) had hemoptysis, which is usually considered
as an expression of angioinvasion by the fungus. Furthermore,
13/34 patients even had a positive GM test in serum (cut off 0.5
ODI), which was also significantly associated with hemoptysis
compared to those without hemoptysis (52% vs. 9%; p = 0.02).
Therefore it is highly likely that a high proportion of patients
in that study might have had a more invasive stage of disease
comparable to SAIA or even IPA, which was not the case for our
study cohort.
Taken this together it may not be surprising that the
sensitivity of GM in BALF, which was initially developed for
the diagnosis of IPA, was considerably lower in our study than
compared to previous study results. It has to be considered
that the vast majority of patients with CPA do not have
SAIA. Thus, the diagnostic performance of GM from BALF
to establish the diagnosis of CPA is insufficient. However, its
high specificity may help to exclude semi-invasive or invasive
disease in certain cases. We suggest that patients with a high
GM test are at least in a transition stage to semi-invasive
or invasive disease, while patients with a non-invasive CPA
subtype usually do not respond with a positive GM from
BALF. Other factors that may influence the performance of
GM in BALF include antifungal treatment, certain antimicrobial
drugs (e.g., beta-lactam antibiotics), underlying diseases (e.g.,
allergic bronchopulmonary aspergillosis), or BALF sampling
bias (e.g., volume and site of lavage fluid sampling). However,
bronchoscopy is still indispensable and should be integrated
in every diagnostic work-up, if possible. Histology (e.g., from
transbronchial biopsies) is still the reference standard to
differentiate between invasive and non-invasive aspergillosis and
to exclude alternative diagnosis as recommended by the current
guideline (Denning et al., 2016). BALF also offers the possibility
to collect fungal cultures from primary site of infection and when
positive, to examine antifungal in vitro susceptibility (Alastruey-
Izquierdo et al., 2018; Godet et al., 2018).
We did not evaluate GM test in serum, because serum was only
availably in a minority of CPA patients included. Furthermore,
previous studies clearly demonstrated that GM testing from
serum has a very low sensitivity and specificity between 23 and
67% and 64 and 85% with an ODI ≥ 0.7 in CPA patients, which
is plausible considering that CPA is a localized chronic disease of
the lung without angioinvasion per definition (Izumikawa et al.,
2012; Shin et al., 2014; Urabe et al., 2017).
This is to our knowledge the first study investigating cytokine
levels in BALF from CPA patients. Generally, CPA patients had
cytokine levels in BALF that were comparable to those found
in patients with respiratory disorders and suspected infection
but without CPA. However, CPA patients had significantly
higher cytokine levels when compared to healthy individuals.
Previous genetic association studies suggested that patients with
CPA might produce lower levels of IL-10 and have ongoing
or higher expression of IL-1b and IL-6 leading to a pro-
inflammatory response and disease progression (Sambatakou
et al., 2006; Smith et al., 2014). In our analysis IL-10 levels
did not differ between CPA patients compared to patients with
respiratory disorders without CPA (p = 0.541), but tended to
be higher compared to healthy individuals (p = 0.072), where
IL-10 levels were often below the detection limit. Levels of
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FIGURE 4 | Box plots of bronchoalveolar lavage fluid (BALF) interleukin (IL)-1β, IL-6, IL-8, IL-10, IL-15, interferon-γ, and tumor necrosis factor (TNF)-α in patients
with chronic pulmonary aspergillosis (CPA), patients with respiratory disorders without CPA and healthy individuals.
IL-1b, IL-6, IL-8, TNF-α, and IFN-γ were significantly higher
in CPA patients compared to healthy individuals (p < 0.001
and p = 0.008, respectively), but not different than in patients
with respiratory disorders without CPA. This stands in contrast
with previous suggestions that CPA might be associated
with low levels of IFN-γ (Doffinger D, AAA2014 Abstract)
and that TNF-α might be linked with aspergillosis and/or
chronic cavitary pulmonary asergillosis (Sambatakou et al.,
2006).
This analysis has several limitations including the small group
size, however, at least in GM a power of over 0.8 was found
during the subsequent power analysis. With regard to the LFD,
no statement can be made about significant differences or test
performance, as only three LFD tests were positive in total.
Furthermore, some biomarkers have a very wide range; the
mean values are partly outside the third quartile. Box plots
showed that, regardless of extreme values and outliers, the
values are systematically unequal (or equal) distributed across
the individual groups. Furthermore, non-parametric tests were
used to minimize distortions due to non-normal distribution
and variance heterogeneity. Another limitation is the lack of a
reference standard for the diagnosis of patients with CPA (e.g.,
growth in transbronchial biopsies/histopathology showing fungal
elements). Although accepted by ESCMID, ERS, and ECMM the
clinical definition of CPA is ambiguous and may be incorrect in a
certain number of patients.
CONCLUSION
Both GM and LFD showed insufficient performance for
diagnosing CPA, with sensitivities of BALF GM below 50%, and
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sensitivity of the LFD below 10%. The high specificities may,
however, result in a high positive predictive value and thereby
help to identify semi-invasive or invasive disease. This has direct
clinical implications, because CPA patients with SAIA have a
more rapid disease progression and should be managed like
patients with IPA. Any diagnostic assay to proof mycological
evidence needs to be interpreted in the clinical and radiological
context as recommended by current guidelines.
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